Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System Clinical Study
A Randomized Controlled Trial of the Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System in Patients With Coronary Artery Disease: BIOHEART-II
Sponsor: CCRF Inc., Beijing, China
Listed as NCT03284255, this NA trial focuses on Antineoplastic Agents and Coronary Artery Disease and remains ongoing. Sponsored by CCRF Inc., Beijing, China, it has been updated 9 times since 2017, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Unknown NA
-
Sep 2024 — Sep 2025 [monthly]
Unknown NA
Status: Active Not Recruiting → Unknown
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting NA
-
Jan 2021 — Jul 2024 [monthly]
Active Not Recruiting NA
-
Dec 2019 — Jan 2021 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
▶ Show 4 earlier versions
-
Jun 2018 — Dec 2019 [monthly]
Recruiting NA
-
Dec 2017 — Jun 2018 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Nov 2017 — Dec 2017 [monthly]
Not Yet Recruiting NA
-
Oct 2017 — Nov 2017 [monthly]
Not Yet Recruiting NA
First recorded
Sep 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- CCRF Inc., Beijing, China
- Shanghai Bio-heart Biological Technology Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Beijing, China , Cangzhou, China , Changchun, China , Changsha, China , Dalian, China , Fuzhou, China , Guangzhou, China , Hangzhou, China , Hohhot, China , Jinan, China and 10 more locations